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Summary: The performance of an homogeneous enzyme immunoassay (EMIT®) for paracetamoi (acetamino-
phen) äs configured for the aca® series of discretionary analysers (Du Pont de Nemours) was evaluated. The
method äs initially formulated by the manufacturers gave unacceptable, performance which was improved
upon, by reagent reformulation and improved kit manufacture procedures, by the manufacturer. The method
was fast, precise and free from interference from a ränge of metabolites, drugs and endogenous physiological
compounds. There was good correlation between this method and an enzymatic method for paracetamoi
(ace taminophen).
Erfahrungen mit einem homogenen Immunassay für Paracetamoi (Acetaminophen)
Zusammenfassung: Ein homogener Enzymimmunassay (EMIT®) für Paracetamoi (Acetaminophen), ausge-
legt für die aca®-Serie diskreter Analysatoren (DuPont de Nemours), wurde kritisch geprüft. Die ursprünglich
vom Hersteller zusammengestellte Methode ergab ein unannehmbares Prüfergebnis. Sie wurde deshalb durch
eine neue Zusammenstellung der Reagenzien und verbesserte Testbesteck-Fabrikationsverfahren durch den
Hersteller verbessert. Die Methode ist schnell, genau und frei von Interferenzen durch eine Reihe von
Stoffwechselprodukten, Arzneimitteln und endogenen physiologischen Verbindungen. Es wurde eine gute
Korrelation zwischen dieser Methode und einer enzymatischen Methode für Paracetamoi (Acetaminophen)
festgestellt.
Introduction
The quantitation of paracetamoi (acetaminophen) in
blood is an impprtant investigation in the diagnosis
and management of patients suspected of taking an
overdose of the drug (1). Accurate quantitation is
important in samples taken no earlier than four hours
after ingestion since absorption is incomplete before
four hours and available antidotes are effective if
treatment is commenced within ten hours of ingestion
(2). Consequently, an assay that is both rapid and
specific is required for routine use.
Amomgst the many methods available for the meas-
urement of paracetamoi there are several which do
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not offer the required specificity (3). This specificity
is offered by both gas-liquid and high performance
liquid Chromatographie techniques (4, 5). However,
these are not techniques which can be held in readi-
ness for immediate use on a twenty four hour basis.
More recently method specificity has been achieved
with the use of enzymes (6) and antibodies (7).
We report an evaluation of a homogeneous enzyme
immunoassay technique for the measurement of para-
cetamoi. The method uses the principle of enzyme-
multiplied immunoassay (EMIT®) with a gIucose-6-
phosphate dehydrogenase (EC 1.1.1.49) label (7) and
has been configured for use on the aca® series of
discretionary analysers manufactured by Du Pont.
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Materials and Methods
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The immunoassays were performed on the Du Pont aca® SX
discretionary analyser (E. I. Du Pont de Nemours, Wilmington,
U. S. A.). The Instrument was set up and maintained, and
quality control procedures followed, exactly in accordance with
the manufacturers instructions.
Reagents
The reagents conformed to the well established EMIT® (Syva,
Palo Alto, U. S. A.) principle s configured for the aca® ana-
lyser Systems (8). All of the operational parameters are fixed
and all the test packs configured, by the manufacturer, to pre-
determined performance specifications within the constraints
imposed by the operational parameters and System design.
A calibration curve was prepared by assaying six calibrators in
quintuplicate and the linearisation parameters of the curve
stored in the Instruments Computer. The manufacturers claim
that, once calibrated, further recalibration is unnecessary for
12 weeks for a given pack lot. The reagent test packs for this
evaluation were provided in two lots. Data will be presented
to show that unacceptable performance of the method noted
with the initial pack lot provided was improved by changes
made, by the manufacturer, in the formulation of the reagents,
in particular the precision of filling of the reagent bubbles in
the test packs and the choice of antibody and drug-enzyme
conjugate.
Enzyme mediated assay
The assay is based on the use of the bacterial enzyme aryl acyl
amidohydrolase (EC 3.5.1.13) which degrades paracetamol to
4-aminophenol and acetate (6). The 4-aminophenol is detected
with o-cresol and ammoniacal copper(Il) sulphate. The method
protocol is s described by Hammond et al. (9) which involves
the addition of 50 μΐ of serum or plasma to 1 ml of enzyme
reagent and, after incubation at room temperature for two
minutes, 1 ml each of o-cresol and amraoniacal copper(II) sul-
phate reagents. After a further incubation for two minutes the
absorbance is read at 615 nm.
Procedures and Results
Precision
Seven serum pools were prepared with varying paracetamol
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Tab. 1. Within and between batch precision for the paraceta-
mol assay.
Material
Within batch
Serum pool
Serum pool
Serum pool
QA material
QA material
Calibrator
Calibrator
Calibrator
Between batch
Serum pool
Serum pool
Serum pool
QA material
QA material
Calibrator
Calibrator
Calibrator
Pack
lot
1
2
1
2
\
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
Mean
concen-
trfltinnu aiiAjii
(mmol/1)
,0.305
0.379
0.658
0.736
0.881
1.042
0.316
0.320
0.872
0.946
0.069
0.064
0.335
0.321
1.297
1.200
0.305
0.381
0.632
0.735
0.938
1.036
0.310
0.324
0.852
0.933 <.
 ;
0.0702
0.0669
0.331
0.333
1.367
1.315
S.D.
• i
0.0113
0.0164
0.0248
0.0184
0.0548
0.0259
0.0140
0.0084
0.0697
0.0286
0.0041
0.0033
0.0145
0.0099
0.1111
0.0291
0.0175
0.0118
0.0387
0.0209
0.0890
0.0339
0.0138
0.0087
0.0514
: 0.0297
0.0047
0.0037
0.023
0.0078
0.1447
0.0345
C.V.
(%)
3.7
4.3
4.5
2.5
6.2
2.5
2.1
2.6
8.0
3.0
5.9
5.2
4.3
3.1
8.9
2.4
5.7
3.1
6.1
2.8
9.5
3.3
6.0
2.7
7.8
3.2
6.7
5.5
7.0
2.3
10.6
2.6
n
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
free human serum spiked with the parent drug. Two pools were
prepared from EMIT® calibrator Solutions. Two further pools
were prepared from assayed quality control materials (Ortho
TDM control levels II and III, Ortho Diagnostic Systems Inc.,
Raritan, New Jersey, U. S. A.). Aliquots of each pool were
stored at -20 °C until assayed. The within batch precision was
performed by assaying each pool twenty times in a continuous
analytical run. The between day precision was assessed by
assaying each pool on twenty working days.
The data for both pack lots are shown in table 1.
Stability of calibration
After the initial calibration, verification of this calibration was
carried out at weekly intervals for the duration of the study
This verification procedure was carried out for both lots of test
packs provided.
The data are shown in figure 1.
Dilution Curve
A serum sample known to contain approximately 1.3 mmol/1
paracetamol was diluted in varying proportions with a paracet-
amol-free serum sample. Similarly the top calibrator was diluted
with the zero calibrator in the same proportions s above. The
resultant dilutions of the serum pools and calibrators were
assayed in duplicate.
The data are shown in figure 2. Linear regression
analysis of the data gave (observed) = 0.937 χ (ex-
pected) -0.011 with a correlation coefficient f 0.996
for the serum pools, and (observed) = 0.976 χ (ex-
pected) + 0.016 with a correlation coefficient of 0.998
for the calibrators.
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Fig. 1. Analysisofcalibratorsoveraperiodof 8 weeks toshow Fig. 2. Dilution curves for the EMIT® paracetamol with a
the stability of calibration for pack lot l (o) and pack patient's sample (o) and a calibrator (o) being diluted
lot 2 (o). with the zero calibrator.
Recovery
Duplicate determinations of the paracetamol concentration
were made on ten drug-free serum samples spiked in the propor-
tion 9 : l with aqueous paracetamol Solutions of 3.0 and 10.0
mmol/l.
The recovery of paracetamol was found to be within
the r nge 96.7-102.0% at 0.3 mmol/l and
90.3-101.4% at 1.0 mmol/l, with mean values of
98.7 and 96.2% respectively.
Method Comparison
Using the first lot of test packs a total of 133 patient samples
known to contain paracetamol, within the stated assay r nge
(0.06—1.32 mmol/l), were assayed by the immuno- and enzym-
atic procedures. A further 25 samples were collected and as-
sayed using the second lot of test packs and the enzymatic
procedure.
The data are shown in figure 3.
Interferences
Paracetamol metabolites
Aqueous stock Solutions of the paracetamol conjugates, the
cysteine, glucuronide, mercapturate and sulphate were diluted
with a seram pool containing 0.3 mmol/l paracetamol. The
metabolites were diluted to three concentrations with the serum
pool and the pafacetamql concentration determined in dupli-
cate. Deionised water replaced the met bolite Solutions in the
controls.
No interference was observed for any of the metab-
olites up to the concentration stated, namely cysteine
(200 mg/1), glucuronide (2000 mg/1), mercapturate
(2000 mg/1) and sulphate (2000 mg/1).
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Fig. 3. Comparison of paracetamol results for the Du Pont
aca® and enzymatic methods. Regression parameters,
according to the Deming procedure, are y = 0.997x
—0.003, r = 0.991, n = 133. Results shown in open
circles used pack lot 2 and were excluded from the
regression analysis.
Paracetamol overdose antidotes
The use of thiol-containing compounds in the treat-
ment of patients who have ingested excessive amounts
of paracetamol is now well accepted (10). The pos-
sible interference of several of the commonly uscd
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antidotes was tested using the satne protocol s em-
ployed for the metabolites. No interference was ob-
served for any of the antidotes up to the concentra-
tion stated, namely N-acetyl cysteine (2000 mg/1),
cysteamine (2000 mg/1), cysteine (2000 mg/1) and
methionine (2000 mg/1).
Common drugs
The protocol described for the paracetamol metabolites was
used for twenty five common drugs and compounds structurally
related to paracetamol. Each drug was dissolved in an appropri-
ate solvent to give a stock solution and the relevant solvent
was used to dilute the serum pool in the controls. The potential
interferent was tested at three concentrations.
No interference was observed with any of the drugs
tested up to the concentration stated in table 2.
Haemolysis, icterus and lipaemia
Serum pools with elevated haemoglobin, bilirubin and triglycer-
ide concentrations 'were shown to be drug free s were two
normal serum pools. Each of the pools was spiked to paraceta-
mol concentrations of approximately 0.3 and 1.0 mmol/l by
the addition of stock aqueous paracetamol Solutions of 3.0 and
10.0 mmol/l. The haemolysed, icteric and lipaemic spiked pools
were diluted with the spiked normal serum pools in varying
proportions and the paracetamol concentrations in each dilu-
tion determined in duplicate.
The data are shown in figure 4.
Tab. 2. Drugs tested for interference in the paracetamol
method. No interference was noted, and each drug was
tested at three concentrations up to the concentrations
indicated in brackets (mg/1 in all cases).
Drug tested c(mg/l)
Acetanilide
Amitriptyline
Acetylsalicylate
Amylobarbitone
Amphetamine
Caffeine
Carbamazepine
Codeine
Diazepam
Imipramine
Lidocaine
Methadone
Methaqualone
N-Acetylprocainamide
Phenacetin
Phenytoin
Phenobarbitone
Procainamide
Phenylephrine
Propoxyphene
Quinidine
Salicylic Acid
Secobarbital
Theophylline
Valproate
2000
2000
4000
2000
1000
2000
2000
2000
200
2000
2000
2000
2000
2000
2000
2000
2000
2000
2000
2000
2000
4000
2000
2000
2000
0.35 r
0.33
l 1.00 r-
S 0.96
σCL
0.92
0.88
100 200
Bilirubin [μΡηοΙ/ΐ] 300
Triglycerides [mmol/lj
50
—A Haemoglobin [μπηοΐ/ΐ] 100
Fig. 4. Effect of haemolysis, icterus and lipaemia on the re^
covery of paracetamol in the Du Pont acd® method at
two paracetamol concentrations.
Renal patient sera
Serum from patients with renal failure may be ex-
pected to contain raised levels of endogeneous phe-
nolic compounds which might be expected to interfere
in the assay.
A total of twenty serum samples from patients with chronic
renal failure (creatinine 196—1510 μπιοΙ/1) were tested in a
recovery experiment with the addition of paracetamol to 0.5
mmol/l. Deionised water replaced the paracetamol in the con-
trols.
The recovery of paracetamol was within the r nge 95
to 111 % with a mean of 102% for the twenty samples.
Discussion
Methods for the measurement of paracetamol should
be rapid and specific since clinical experience in the
management of patients who have taken an overdose
of paracetamol suggests that s ccessful tre tinent de-
pends on quantitation of the parent drug between
four and ten hours after drug irigestion (10).
The homogeneous enzyme immunoassay for parace-
tamol s° configured for the aca® series of discrete
analysers described offers a rapid, sp.ecific and precise
method for the parent drug. * ;
J. Clin. Chem. Clin. Bipchem. / Vol. 24, 1986 / No. 2
Campbell and Price: Homogeneous iramunoassay for paracetaraol 159
Initially the precision of the assay, especially at para-
cetamol concentrations close to the top calibrator,
was unacceptable. This was reflected in the variability
of the value of the top calibrator observed in the
weekly calibration checks and probably also ac-
counted for the spread of points in the method com-
parison. The second lot of test packs, which were
prepared to overcome this initial imprecision, by in-
creasing the rate of absorbance change differential
between the 1.0 and 1.3 mmol/1 paracetamol calibra-
tors, improved the precision dramatically (tab. 1). As
was expected, the variability in the top calibrator
value observed in the weekly calibration checks also
became less.
Apart from these problems the assay showed good
analytical recovery and was unaffected by a r nge of
metabolites. This latter group are perhaps the most
important interferents to consider s in several
methods they lead to the overestimation of the drug
concentration by hydrolysis of the metabolites to
parent drug (3, 10). No significant interference was
found with compounds administered s antidotes to
paracetamol poisoning nor with any of twenty five
commonly prescribed drugs. There was no significant
interference from the physiological interferents hae-
moglobin, lipaemia or bilirubin. In the case of the
high paracetamol pool spiked with these compounds
the variability can be attributed to the poor precision
of the method at this concentration seen with the
first pack lot provided. Samples from patients with
chronic renal failure (creatinine 196 — 1510 μιηοΐ/l)
were also without effect. The homogeneous immuno-
assay described offers an alternative rapid method
for the determination of paracetamol. In common
with the enzymatic assay (9) it is specific for the
parent compound, a specificity which has been, to
date, offered by the Chromatographie procedures.
The combination of the described assay with a fully
automated System such s the Du Pont aca® series
of analysers, where strict control of all aspects of
the analytical System, e. g. temperature, pipetting,
absorbance measurement and reagent manufacture
are possible, yields a highly stable and precise assay
for paracetamol.
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